Emergo Therapeutics Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
8
- Latest Deal Type
-
Out of Business
Emergo Therapeutics General Information
Description
Developer of therapeutic drugs designed to improve immune system function in various indications. The company's drugs target the release of inflammatory molecules including developing drugs for the treatment of uncomplicated influenza and improving the immune system, enabling doctors to prevent damaging symptoms and outcomes of seemingly unrelated diseases.
Contact Information
Website
www.emergotherapeutics.comCorporate Office
- 6208 Fayetteville Road
- Suite 104
- Durham, NC 27713
- United States
Corporate Office
- 6208 Fayetteville Road
- Suite 104
- Durham, NC 27713
- United States
Emergo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 30-Sep-2026 | Completed | Out of Business | |||
| 5. Later Stage VC | 06-May-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 12-Oct-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Debt - General | 16-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 23-May-2018 | $12M | $12.1M | Completed | Clinical Trials - Phase 1 | |
| 1. Debt - General | 23-Aug-2017 | $75K | $75K | Completed | Clinical Trials - Phase 1 |
Emergo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Emergo Therapeutics Patents
Emergo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3040420-A1 | Mast cell stabilizers for treatment of chronic inflammatory conditions | Active | 18-Oct-2016 | ||
| EP-3528809-A1 | Mast cell stabilizers for treatment of chronic inflammatory conditions | Inactive | 18-Oct-2016 | ||
| EP-3528809-A4 | Mast cell stabilizers for treatment of chronic inflammatory conditions | Inactive | 18-Oct-2016 | ||
| US-11478463-B2 | Mast cell stabilizers for treatment of chronic inflammatory conditions | Active | 18-Oct-2016 | ||
| US-20200215049-A1 | Mast cell stabilizers for treatment of chronic inflammatory conditions | Active | 18-Oct-2016 | A61K31/4535 |
Emergo Therapeutics Signals
Emergo Therapeutics FAQs
-
When was Emergo Therapeutics founded?
Emergo Therapeutics was founded in 2016.
-
Where is Emergo Therapeutics headquartered?
Emergo Therapeutics is headquartered in Durham, NC.
-
What is the size of Emergo Therapeutics?
Emergo Therapeutics has 8 total employees.
-
What industry is Emergo Therapeutics in?
Emergo Therapeutics’s primary industry is Drug Discovery.
-
Is Emergo Therapeutics a private or public company?
Emergo Therapeutics is a Private company.
-
What is Emergo Therapeutics’s current revenue?
The current revenue for Emergo Therapeutics is .
-
How much funding has Emergo Therapeutics raised over time?
Emergo Therapeutics has raised $16.6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process